Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated a notable increase in the volume of EsoGuard tests processed, with a climb from 2,756 tests in Q2 to 2,841 in Q3, indicating a positive growth trend in its Diagnostics segment. The company's current valuation presents an attractive opportunity, especially as it anticipates significant growth in its medical devices and digital health segments moving into 2025 and 2026. With a balanced risk-reward profile highlighted by the upward trajectory of its testing figures and projections for substantial future growth, PAVmed is positioned favorably within the medical technology market.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million in its recent quarter, signaling financial challenges as earnings per share fell to $(0.05), deviating negatively from both internal and consensus estimates. The company experienced a decline in its EsoGuard tests, processing only 2,756 tests in Q2 compared to 3,034 in Q1 and a higher volume in previous quarters, indicating potential issues in product uptake and market demand. Furthermore, PAVmed faces substantial risks impacting its growth prospects, including liquidity issues, regulatory hurdles, commercialization challenges, and increased competition within the medical technology sector.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Jan 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.